van Hall T, van de Rhee N E, Schoenberger S P, Vierboom M P, Verreck F A, Melief C J, Offringa R
Department of Immunohematology and Blood Bank, Leiden University Medical Center, The Netherlands.
Cancer Res. 1998 Jul 15;58(14):3087-93.
Murine tumor cells obtained through transfection of expression plasmids carrying activated cellular and/or viral oncogenes constitute formidable tools for immunological tumor research. As reported previously, mouse embryo cells of C57BL/6 origin, transformed by mutated p53 or human papilloma virus type 16 (HPV16), present, at their surface, MHC-bound peptides that are derived from the p53 and the HPV16 E7 oncoproteins, respectively, which can serve as a target for a highly effective antitumor T-cell response. Here, we describe the identification, through molecular cloning, of an additional, highly immunodominant peptide that is presented by the aforementioned HPV16- and p53-transformed cells. This peptide is encoded by a cryptic open reading frame in the backbone sequences of the plasmids that had been used to generate these cells. Considerable amounts of transcripts encompassing this open reading frame were detected in the cells concerned. These transcripts were the result of the bidirectional nature of the retroviral long terminal repeat (LTR) present in the expression plasmids used for transfection, which resulted in transcription of the gene of interest, as well as in transcription of the vector sequences positioned at the other side of the LTR. Due to this mechanism, all tumor cells harboring LTR-driven expression plasmids expressed the highly immunogenic peptide, whereas cells containing plasmids driven by more unidirectional promoters exhibited lower levels of this peptide. LTR-driven expression plasmids were also shown to encode this peptide epitope when used for DNA vaccination, as mice vaccinated with such a plasmid developed a CTL response against this peptide. Our data show that awareness of plasmid backbone-derived epitopes is of crucial importance for the correct interpretation of preclinical experiments and for the design of DNA vaccines.
通过转染携带活化的细胞和/或病毒癌基因的表达质粒获得的小鼠肿瘤细胞,是免疫肿瘤学研究的强大工具。如先前报道,由突变型p53或人乳头瘤病毒16型(HPV16)转化的C57BL/6来源的小鼠胚胎细胞,在其表面呈现分别源自p53和HPV16 E7癌蛋白的MHC结合肽,这些肽可作为高效抗肿瘤T细胞反应的靶点。在此,我们描述了通过分子克隆鉴定出的另一种高度免疫显性肽,该肽由上述HPV16和p53转化细胞呈递。此肽由用于生成这些细胞的质粒主干序列中的一个隐蔽开放阅读框编码。在相关细胞中检测到了大量包含该开放阅读框的转录本。这些转录本是用于转染的表达质粒中存在的逆转录病毒长末端重复序列(LTR)双向性质的结果,这导致了目的基因的转录以及位于LTR另一侧的载体序列的转录。由于这种机制,所有携带LTR驱动表达质粒的肿瘤细胞都表达了高度免疫原性的肽,而含有由更单向启动子驱动的质粒的细胞则表现出较低水平的该肽。当用于DNA疫苗接种时,LTR驱动的表达质粒也显示编码这种肽表位,因为用这种质粒接种的小鼠产生了针对该肽的CTL反应。我们的数据表明,认识到质粒主干衍生的表位对于正确解释临床前实验和设计DNA疫苗至关重要。